GoAI
Get started
Johnson & Johnson logo

Johnson & Johnson

JNJ

NYSEHealthcareDrug Manufacturers - General

Open in GoAI

Previous close

$270.24

+$2.87 · +1.07%

Aug 21, 4:00 PM ET

JNJ company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

69

Undervalued

Momentum

61

Gaining

Sentiment

70

Bullish

Risk resilience

84

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
US
CEO
Joaquin Duato
Listed since
Jan 2, 1962
Employees
141,700

Market position

Day range

Current $270.24

52-week range

Current $270.24

Open
$267.57
Previous close
$267.37
Volume
6.18M
0.78× average
Average volume
7.94M
Average daily volume
Market cap
651.25B USD
Beta
0.23
Market reference 1
50-day average
$254.83
+6.05% above average
200-day average
$231.81
+16.58% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
31.24×
P/B (TTM)
7.76×
P/S (TTM)
6.65×
Dividend yield
1.94%

Profitability & efficiency

Gross margin
70.45%
Operating margin
26.81%
Net margin
21.48%

Financial health

Debt / equity
0.58×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends78%56%33%10%Gross margin, FY2021: 70.28%Gross margin, FY2022: 69.25%Gross margin, FY2023: 68.82%Gross margin, FY2024: 69.07%Gross margin, FY2025: 72.78%Operating margin, FY2021: 26.60%Operating margin, FY2022: 26.27%Operating margin, FY2023: 27.49%Operating margin, FY2024: 24.94%Operating margin, FY2025: 27.17%Net margin, FY2021: 26.52%Net margin, FY2022: 22.43%Net margin, FY2023: 41.28%Net margin, FY2024: 15.84%Net margin, FY2025: 28.46%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 70.28%. Gross margin FY2022 69.25%. Gross margin FY2023 68.82%. Gross margin FY2024 69.07%. Gross margin FY2025 72.78%. Operating margin FY2021 26.60%. Operating margin FY2022 26.27%. Operating margin FY2023 27.49%. Operating margin FY2024 24.94%. Operating margin FY2025 27.17%. Net margin FY2021 26.52%. Net margin FY2022 22.43%. Net margin FY2023 41.28%. Net margin FY2024 15.84%. Net margin FY2025 28.46%.

Income trends

Revenue

94.19B USD+6.05%

Operating income

25.6B USD+15.56%

Net income

26.8B USD+90.56%
Income trends across reported periods102.21B USD70.15B USD38.1B USD6.05B USDRevenue, FY2021: 78.74B USDRevenue, FY2022: 79.99B USDRevenue, FY2023: 85.16B USDRevenue, FY2024: 88.82B USDRevenue, FY2025: 94.19B USDOperating income, FY2021: 20.94B USDOperating income, FY2022: 21.01B USDOperating income, FY2023: 23.41B USDOperating income, FY2024: 22.15B USDOperating income, FY2025: 25.6B USDNet income, FY2021: 20.88B USDNet income, FY2022: 17.94B USDNet income, FY2023: 35.15B USDNet income, FY2024: 14.07B USDNet income, FY2025: 26.8B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 78.74B USD. Revenue FY2022 79.99B USD. Revenue FY2023 85.16B USD. Revenue FY2024 88.82B USD. Revenue FY2025 94.19B USD. Operating income FY2021 20.94B USD. Operating income FY2022 21.01B USD. Operating income FY2023 23.41B USD. Operating income FY2024 22.15B USD. Operating income FY2025 25.6B USD. Net income FY2021 20.88B USD. Net income FY2022 17.94B USD. Net income FY2023 35.15B USD. Net income FY2024 14.07B USD. Net income FY2025 26.8B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue94.19B USD88.82B USD85.16B USD79.99B USD78.74B USD
Cost of goods sold25.64B USD27.47B USD26.55B USD24.6B USD23.4B USD
Gross profit68.56B USD61.35B USD58.61B USD55.39B USD55.34B USD
Research and development14.67B USD17.23B USD15.09B USD14.14B USD14.28B USD
Selling, general, and administrative23.68B USD21.97B USD20.11B USD20.25B USD20.12B USD
Operating expenses42.96B USD39.2B USD35.2B USD34.38B USD34.4B USD
Interest income1.06B USD1.33B USD1.26B USD490M USD53M USD
Interest expense971M USD755M USD772M USD276M USD183M USD
Depreciation and amortization7.5B USD7.34B USD7.49B USD6.97B USD7.39B USD
Operating income25.6B USD22.15B USD23.41B USD21.01B USD20.94B USD
Net income26.8B USD14.07B USD35.15B USD17.94B USD20.88B USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
11.03
FY2025 · +90.50% year over year
Latest fiscal-year revenue
94.19B USD
FY2025 · +6.05% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend14.5111.348.175FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend95.74B89.56B83.38B77.19BFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

40 ratings
Strong buy00%
Buy2153%
Hold1640%
Sell38%
Strong sell00%

Recent analyst actions

12 institutions

JNJ peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

—

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

—

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

—

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

—

Novartis AG logo

NVS

Novartis AG

$158.86

—

AstraZeneca PLC logo

AZN

AstraZeneca PLC

$165.98

—

ETFs holding JNJ

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.65B
Weight
0.85%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
16.2B
Weight
0.96%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
8.68B
Weight
0.98%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31+0.39%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
8B
Weight
0.98%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
Vanguard Morningstar Value ETF logoVanguard Morningstar Value ETFVTV
Market value
5.88B
Weight
2.29%
AUM
256.5B USD
Expense ratio
0.03%
Price / 1D
$226.4+0.54%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
4.63B
Weight
10.34%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%
Vanguard Dividend Appreciation ETF logoVanguard Dividend Appreciation ETFVIG
Market value
3.49B
Weight
2.66%
AUM
130.9B USD
Expense ratio
0.04%
Price / 1D
$243.91+0.69%
Vanguard High Dividend Yield ETF logoVanguard High Dividend Yield ETFVYM
Market value
2.49B
Weight
2.50%
AUM
99.2B USD
Expense ratio
0.04%
Price / 1D
$164.97+0.59%

Continue in GoAI

Research JNJ

research.disclaimer